COVID-19 Begins To Impact Drug Supplies; Infections Accelerate in Iran, Across Europe & United States 04/03/2020 Elaine Ruth Fletcher As the COVID-19 continued its march across the planet, shortages of some key drug ingredients were beginning to be felt in some markets, and iconic events such as the World Bank’s annual spring meeting were to be moved to a virtual platform. In Geneva, parallel sessions and side events involving the ongoing annual meetings of […] Continue reading -> Former Director Of Italian Medicines Agency Recognized For Drug Transparency Work 26/02/2020 Editorial team Former general director of the Italian Medicines Agency (AIFA) Luca Li Bassi was awarded the 2019 “International Transparency in Medicines Policies Awards” by the French civil society watchdog group l’Observatoire Médicaments Transparences (the Observatory for Transparency in Medicines), for his efforts in negotiating a milestone World Health Assembly resolution in May 2019 supporting more public […] Continue reading -> WHO Protests Price Shocks & Hoarding Of Vital Protective Gear Needed To Fight Coronavirus; WHO Executive Board Calls For More Preparedness 07/02/2020 Elaine Ruth Fletcher The world is facing a “severe disruption” in stocks of personal protective equipment vital for health workers to fight the novel coronavirus raging through China’s Hubei Province and threatening other countries worldwide, said WHO Director-General Dr Tedros Adhanom Ghebreyesus at a Friday press briefing. The Director-General spoke as cases of the new (2019-nCoV) virus continued […] Continue reading -> WHO Needs To Accelerate New Polio Vaccine Rollout & Action On Harmful Alcohol Consumption, Says Executive Board 07/02/2020 Elaine Ruth Fletcher, Grace Ren & Catherine Saez After a total of 12.5 hours of consultations in five informal meetings, a bloc of countries led by Thailand won WHO Executive Board approval for a landmark decision to develop a new ten year-action plan to reduce the harmful use of alcohol. Representatives of Norway and the European Union joined as co-sponsors in a compromise […] Continue reading -> Controversy Swirls Over WHO Alcohol Reduction Strategy 06/02/2020 Elaine Ruth Fletcher WHO member states were locked away in late-night negotiations over the shape of a proposed new WHO roadmap for reducing harmful alcohol consumption. A group of member states, led by Bangladesh, Indonesia, Iran, Sri Lanka and Thailand, have been pressing the WHO Executive Board (EB) to support the rapid development of a tough new WHO […] Continue reading -> Measles & Meningitis Elimination – WHO EB Sets Direction For Next Decade Of Vaccines Action 05/02/2020 Grace Ren The World Health Organization Executive Board unanimously adopted two decisions that began to set the stage for global vaccine policy in the next decade – a draft resolution on “strengthening global immunization efforts to leave no one behind” and another on “eliminating meningitis by 2030,” after reviewing a report prepared by the Director-General on lessons […] Continue reading -> WHO Head Praises China Response To Coronavirus Emergency; Criticizes “Unnecessary” Trade and Travel Restrictions 03/02/2020 Elaine Ruth Fletcher World Health Organization Director General Dr Tedros Adhanom Ghebreyesus called for “solidarity, solidarity and solidarity” amongst WHO member states to meet the new challenge of a novel coronavirus epidemic – at Monday’s opening of a week-long meeting of WHO’s Executive Board in Geneva. “The rule of the game is solidarity, solidarity, solidarity. But we see […] Continue reading -> Emergencies, Cervical Cancer, IP & Innovation Among Highlights Of Member State Consultations Ahead Of WHO Executive Board 09/01/2020 Editorial team Ahead of the upcoming WHO Executive Board meeting 3-8 February, WHO has launched a series of informal consultations this week with member state representatives on key issues that will be coming before the governing body – and ultimately the May meeting of the World Health Assembly (WHA). The detailed consultation agenda, published on the WHO […] Continue reading -> Creative Approaches To Improving Medicines Access – Lessons From The Hepatitis C Experience 06/12/2019 Elaine Ruth Fletcher The issues around access to medicines at affordable prices has galvanized civil society, the pharmaceutical industry, the research community, and politicians this year in oft-contentious debate that shows no sign of abating. A day-long session hosted by the Global Health Centre of Geneva’s Graduate Institute, and cosponsored by the Swiss Institute of Intellectual Property and […] Continue reading -> French Parliament To Require Disclosure Of Public Funds Used In R&D For New Drugs Entering Market 27/11/2019 Grace Ren The lower house of the French parliament has approved a milestone requirement that pharmaceutical companies must disclose the amount of public funding that was used in the research and development of new medicines entering the national market, as well as allowing those contributions to be factored into negotiations over final drug pricing. After being initially […] Continue reading -> Posts navigation Older postsNewer posts
Former Director Of Italian Medicines Agency Recognized For Drug Transparency Work 26/02/2020 Editorial team Former general director of the Italian Medicines Agency (AIFA) Luca Li Bassi was awarded the 2019 “International Transparency in Medicines Policies Awards” by the French civil society watchdog group l’Observatoire Médicaments Transparences (the Observatory for Transparency in Medicines), for his efforts in negotiating a milestone World Health Assembly resolution in May 2019 supporting more public […] Continue reading -> WHO Protests Price Shocks & Hoarding Of Vital Protective Gear Needed To Fight Coronavirus; WHO Executive Board Calls For More Preparedness 07/02/2020 Elaine Ruth Fletcher The world is facing a “severe disruption” in stocks of personal protective equipment vital for health workers to fight the novel coronavirus raging through China’s Hubei Province and threatening other countries worldwide, said WHO Director-General Dr Tedros Adhanom Ghebreyesus at a Friday press briefing. The Director-General spoke as cases of the new (2019-nCoV) virus continued […] Continue reading -> WHO Needs To Accelerate New Polio Vaccine Rollout & Action On Harmful Alcohol Consumption, Says Executive Board 07/02/2020 Elaine Ruth Fletcher, Grace Ren & Catherine Saez After a total of 12.5 hours of consultations in five informal meetings, a bloc of countries led by Thailand won WHO Executive Board approval for a landmark decision to develop a new ten year-action plan to reduce the harmful use of alcohol. Representatives of Norway and the European Union joined as co-sponsors in a compromise […] Continue reading -> Controversy Swirls Over WHO Alcohol Reduction Strategy 06/02/2020 Elaine Ruth Fletcher WHO member states were locked away in late-night negotiations over the shape of a proposed new WHO roadmap for reducing harmful alcohol consumption. A group of member states, led by Bangladesh, Indonesia, Iran, Sri Lanka and Thailand, have been pressing the WHO Executive Board (EB) to support the rapid development of a tough new WHO […] Continue reading -> Measles & Meningitis Elimination – WHO EB Sets Direction For Next Decade Of Vaccines Action 05/02/2020 Grace Ren The World Health Organization Executive Board unanimously adopted two decisions that began to set the stage for global vaccine policy in the next decade – a draft resolution on “strengthening global immunization efforts to leave no one behind” and another on “eliminating meningitis by 2030,” after reviewing a report prepared by the Director-General on lessons […] Continue reading -> WHO Head Praises China Response To Coronavirus Emergency; Criticizes “Unnecessary” Trade and Travel Restrictions 03/02/2020 Elaine Ruth Fletcher World Health Organization Director General Dr Tedros Adhanom Ghebreyesus called for “solidarity, solidarity and solidarity” amongst WHO member states to meet the new challenge of a novel coronavirus epidemic – at Monday’s opening of a week-long meeting of WHO’s Executive Board in Geneva. “The rule of the game is solidarity, solidarity, solidarity. But we see […] Continue reading -> Emergencies, Cervical Cancer, IP & Innovation Among Highlights Of Member State Consultations Ahead Of WHO Executive Board 09/01/2020 Editorial team Ahead of the upcoming WHO Executive Board meeting 3-8 February, WHO has launched a series of informal consultations this week with member state representatives on key issues that will be coming before the governing body – and ultimately the May meeting of the World Health Assembly (WHA). The detailed consultation agenda, published on the WHO […] Continue reading -> Creative Approaches To Improving Medicines Access – Lessons From The Hepatitis C Experience 06/12/2019 Elaine Ruth Fletcher The issues around access to medicines at affordable prices has galvanized civil society, the pharmaceutical industry, the research community, and politicians this year in oft-contentious debate that shows no sign of abating. A day-long session hosted by the Global Health Centre of Geneva’s Graduate Institute, and cosponsored by the Swiss Institute of Intellectual Property and […] Continue reading -> French Parliament To Require Disclosure Of Public Funds Used In R&D For New Drugs Entering Market 27/11/2019 Grace Ren The lower house of the French parliament has approved a milestone requirement that pharmaceutical companies must disclose the amount of public funding that was used in the research and development of new medicines entering the national market, as well as allowing those contributions to be factored into negotiations over final drug pricing. After being initially […] Continue reading -> Posts navigation Older postsNewer posts
WHO Protests Price Shocks & Hoarding Of Vital Protective Gear Needed To Fight Coronavirus; WHO Executive Board Calls For More Preparedness 07/02/2020 Elaine Ruth Fletcher The world is facing a “severe disruption” in stocks of personal protective equipment vital for health workers to fight the novel coronavirus raging through China’s Hubei Province and threatening other countries worldwide, said WHO Director-General Dr Tedros Adhanom Ghebreyesus at a Friday press briefing. The Director-General spoke as cases of the new (2019-nCoV) virus continued […] Continue reading -> WHO Needs To Accelerate New Polio Vaccine Rollout & Action On Harmful Alcohol Consumption, Says Executive Board 07/02/2020 Elaine Ruth Fletcher, Grace Ren & Catherine Saez After a total of 12.5 hours of consultations in five informal meetings, a bloc of countries led by Thailand won WHO Executive Board approval for a landmark decision to develop a new ten year-action plan to reduce the harmful use of alcohol. Representatives of Norway and the European Union joined as co-sponsors in a compromise […] Continue reading -> Controversy Swirls Over WHO Alcohol Reduction Strategy 06/02/2020 Elaine Ruth Fletcher WHO member states were locked away in late-night negotiations over the shape of a proposed new WHO roadmap for reducing harmful alcohol consumption. A group of member states, led by Bangladesh, Indonesia, Iran, Sri Lanka and Thailand, have been pressing the WHO Executive Board (EB) to support the rapid development of a tough new WHO […] Continue reading -> Measles & Meningitis Elimination – WHO EB Sets Direction For Next Decade Of Vaccines Action 05/02/2020 Grace Ren The World Health Organization Executive Board unanimously adopted two decisions that began to set the stage for global vaccine policy in the next decade – a draft resolution on “strengthening global immunization efforts to leave no one behind” and another on “eliminating meningitis by 2030,” after reviewing a report prepared by the Director-General on lessons […] Continue reading -> WHO Head Praises China Response To Coronavirus Emergency; Criticizes “Unnecessary” Trade and Travel Restrictions 03/02/2020 Elaine Ruth Fletcher World Health Organization Director General Dr Tedros Adhanom Ghebreyesus called for “solidarity, solidarity and solidarity” amongst WHO member states to meet the new challenge of a novel coronavirus epidemic – at Monday’s opening of a week-long meeting of WHO’s Executive Board in Geneva. “The rule of the game is solidarity, solidarity, solidarity. But we see […] Continue reading -> Emergencies, Cervical Cancer, IP & Innovation Among Highlights Of Member State Consultations Ahead Of WHO Executive Board 09/01/2020 Editorial team Ahead of the upcoming WHO Executive Board meeting 3-8 February, WHO has launched a series of informal consultations this week with member state representatives on key issues that will be coming before the governing body – and ultimately the May meeting of the World Health Assembly (WHA). The detailed consultation agenda, published on the WHO […] Continue reading -> Creative Approaches To Improving Medicines Access – Lessons From The Hepatitis C Experience 06/12/2019 Elaine Ruth Fletcher The issues around access to medicines at affordable prices has galvanized civil society, the pharmaceutical industry, the research community, and politicians this year in oft-contentious debate that shows no sign of abating. A day-long session hosted by the Global Health Centre of Geneva’s Graduate Institute, and cosponsored by the Swiss Institute of Intellectual Property and […] Continue reading -> French Parliament To Require Disclosure Of Public Funds Used In R&D For New Drugs Entering Market 27/11/2019 Grace Ren The lower house of the French parliament has approved a milestone requirement that pharmaceutical companies must disclose the amount of public funding that was used in the research and development of new medicines entering the national market, as well as allowing those contributions to be factored into negotiations over final drug pricing. After being initially […] Continue reading -> Posts navigation Older postsNewer posts
WHO Needs To Accelerate New Polio Vaccine Rollout & Action On Harmful Alcohol Consumption, Says Executive Board 07/02/2020 Elaine Ruth Fletcher, Grace Ren & Catherine Saez After a total of 12.5 hours of consultations in five informal meetings, a bloc of countries led by Thailand won WHO Executive Board approval for a landmark decision to develop a new ten year-action plan to reduce the harmful use of alcohol. Representatives of Norway and the European Union joined as co-sponsors in a compromise […] Continue reading -> Controversy Swirls Over WHO Alcohol Reduction Strategy 06/02/2020 Elaine Ruth Fletcher WHO member states were locked away in late-night negotiations over the shape of a proposed new WHO roadmap for reducing harmful alcohol consumption. A group of member states, led by Bangladesh, Indonesia, Iran, Sri Lanka and Thailand, have been pressing the WHO Executive Board (EB) to support the rapid development of a tough new WHO […] Continue reading -> Measles & Meningitis Elimination – WHO EB Sets Direction For Next Decade Of Vaccines Action 05/02/2020 Grace Ren The World Health Organization Executive Board unanimously adopted two decisions that began to set the stage for global vaccine policy in the next decade – a draft resolution on “strengthening global immunization efforts to leave no one behind” and another on “eliminating meningitis by 2030,” after reviewing a report prepared by the Director-General on lessons […] Continue reading -> WHO Head Praises China Response To Coronavirus Emergency; Criticizes “Unnecessary” Trade and Travel Restrictions 03/02/2020 Elaine Ruth Fletcher World Health Organization Director General Dr Tedros Adhanom Ghebreyesus called for “solidarity, solidarity and solidarity” amongst WHO member states to meet the new challenge of a novel coronavirus epidemic – at Monday’s opening of a week-long meeting of WHO’s Executive Board in Geneva. “The rule of the game is solidarity, solidarity, solidarity. But we see […] Continue reading -> Emergencies, Cervical Cancer, IP & Innovation Among Highlights Of Member State Consultations Ahead Of WHO Executive Board 09/01/2020 Editorial team Ahead of the upcoming WHO Executive Board meeting 3-8 February, WHO has launched a series of informal consultations this week with member state representatives on key issues that will be coming before the governing body – and ultimately the May meeting of the World Health Assembly (WHA). The detailed consultation agenda, published on the WHO […] Continue reading -> Creative Approaches To Improving Medicines Access – Lessons From The Hepatitis C Experience 06/12/2019 Elaine Ruth Fletcher The issues around access to medicines at affordable prices has galvanized civil society, the pharmaceutical industry, the research community, and politicians this year in oft-contentious debate that shows no sign of abating. A day-long session hosted by the Global Health Centre of Geneva’s Graduate Institute, and cosponsored by the Swiss Institute of Intellectual Property and […] Continue reading -> French Parliament To Require Disclosure Of Public Funds Used In R&D For New Drugs Entering Market 27/11/2019 Grace Ren The lower house of the French parliament has approved a milestone requirement that pharmaceutical companies must disclose the amount of public funding that was used in the research and development of new medicines entering the national market, as well as allowing those contributions to be factored into negotiations over final drug pricing. After being initially […] Continue reading -> Posts navigation Older postsNewer posts
Controversy Swirls Over WHO Alcohol Reduction Strategy 06/02/2020 Elaine Ruth Fletcher WHO member states were locked away in late-night negotiations over the shape of a proposed new WHO roadmap for reducing harmful alcohol consumption. A group of member states, led by Bangladesh, Indonesia, Iran, Sri Lanka and Thailand, have been pressing the WHO Executive Board (EB) to support the rapid development of a tough new WHO […] Continue reading -> Measles & Meningitis Elimination – WHO EB Sets Direction For Next Decade Of Vaccines Action 05/02/2020 Grace Ren The World Health Organization Executive Board unanimously adopted two decisions that began to set the stage for global vaccine policy in the next decade – a draft resolution on “strengthening global immunization efforts to leave no one behind” and another on “eliminating meningitis by 2030,” after reviewing a report prepared by the Director-General on lessons […] Continue reading -> WHO Head Praises China Response To Coronavirus Emergency; Criticizes “Unnecessary” Trade and Travel Restrictions 03/02/2020 Elaine Ruth Fletcher World Health Organization Director General Dr Tedros Adhanom Ghebreyesus called for “solidarity, solidarity and solidarity” amongst WHO member states to meet the new challenge of a novel coronavirus epidemic – at Monday’s opening of a week-long meeting of WHO’s Executive Board in Geneva. “The rule of the game is solidarity, solidarity, solidarity. But we see […] Continue reading -> Emergencies, Cervical Cancer, IP & Innovation Among Highlights Of Member State Consultations Ahead Of WHO Executive Board 09/01/2020 Editorial team Ahead of the upcoming WHO Executive Board meeting 3-8 February, WHO has launched a series of informal consultations this week with member state representatives on key issues that will be coming before the governing body – and ultimately the May meeting of the World Health Assembly (WHA). The detailed consultation agenda, published on the WHO […] Continue reading -> Creative Approaches To Improving Medicines Access – Lessons From The Hepatitis C Experience 06/12/2019 Elaine Ruth Fletcher The issues around access to medicines at affordable prices has galvanized civil society, the pharmaceutical industry, the research community, and politicians this year in oft-contentious debate that shows no sign of abating. A day-long session hosted by the Global Health Centre of Geneva’s Graduate Institute, and cosponsored by the Swiss Institute of Intellectual Property and […] Continue reading -> French Parliament To Require Disclosure Of Public Funds Used In R&D For New Drugs Entering Market 27/11/2019 Grace Ren The lower house of the French parliament has approved a milestone requirement that pharmaceutical companies must disclose the amount of public funding that was used in the research and development of new medicines entering the national market, as well as allowing those contributions to be factored into negotiations over final drug pricing. After being initially […] Continue reading -> Posts navigation Older postsNewer posts
Measles & Meningitis Elimination – WHO EB Sets Direction For Next Decade Of Vaccines Action 05/02/2020 Grace Ren The World Health Organization Executive Board unanimously adopted two decisions that began to set the stage for global vaccine policy in the next decade – a draft resolution on “strengthening global immunization efforts to leave no one behind” and another on “eliminating meningitis by 2030,” after reviewing a report prepared by the Director-General on lessons […] Continue reading -> WHO Head Praises China Response To Coronavirus Emergency; Criticizes “Unnecessary” Trade and Travel Restrictions 03/02/2020 Elaine Ruth Fletcher World Health Organization Director General Dr Tedros Adhanom Ghebreyesus called for “solidarity, solidarity and solidarity” amongst WHO member states to meet the new challenge of a novel coronavirus epidemic – at Monday’s opening of a week-long meeting of WHO’s Executive Board in Geneva. “The rule of the game is solidarity, solidarity, solidarity. But we see […] Continue reading -> Emergencies, Cervical Cancer, IP & Innovation Among Highlights Of Member State Consultations Ahead Of WHO Executive Board 09/01/2020 Editorial team Ahead of the upcoming WHO Executive Board meeting 3-8 February, WHO has launched a series of informal consultations this week with member state representatives on key issues that will be coming before the governing body – and ultimately the May meeting of the World Health Assembly (WHA). The detailed consultation agenda, published on the WHO […] Continue reading -> Creative Approaches To Improving Medicines Access – Lessons From The Hepatitis C Experience 06/12/2019 Elaine Ruth Fletcher The issues around access to medicines at affordable prices has galvanized civil society, the pharmaceutical industry, the research community, and politicians this year in oft-contentious debate that shows no sign of abating. A day-long session hosted by the Global Health Centre of Geneva’s Graduate Institute, and cosponsored by the Swiss Institute of Intellectual Property and […] Continue reading -> French Parliament To Require Disclosure Of Public Funds Used In R&D For New Drugs Entering Market 27/11/2019 Grace Ren The lower house of the French parliament has approved a milestone requirement that pharmaceutical companies must disclose the amount of public funding that was used in the research and development of new medicines entering the national market, as well as allowing those contributions to be factored into negotiations over final drug pricing. After being initially […] Continue reading -> Posts navigation Older postsNewer posts
WHO Head Praises China Response To Coronavirus Emergency; Criticizes “Unnecessary” Trade and Travel Restrictions 03/02/2020 Elaine Ruth Fletcher World Health Organization Director General Dr Tedros Adhanom Ghebreyesus called for “solidarity, solidarity and solidarity” amongst WHO member states to meet the new challenge of a novel coronavirus epidemic – at Monday’s opening of a week-long meeting of WHO’s Executive Board in Geneva. “The rule of the game is solidarity, solidarity, solidarity. But we see […] Continue reading -> Emergencies, Cervical Cancer, IP & Innovation Among Highlights Of Member State Consultations Ahead Of WHO Executive Board 09/01/2020 Editorial team Ahead of the upcoming WHO Executive Board meeting 3-8 February, WHO has launched a series of informal consultations this week with member state representatives on key issues that will be coming before the governing body – and ultimately the May meeting of the World Health Assembly (WHA). The detailed consultation agenda, published on the WHO […] Continue reading -> Creative Approaches To Improving Medicines Access – Lessons From The Hepatitis C Experience 06/12/2019 Elaine Ruth Fletcher The issues around access to medicines at affordable prices has galvanized civil society, the pharmaceutical industry, the research community, and politicians this year in oft-contentious debate that shows no sign of abating. A day-long session hosted by the Global Health Centre of Geneva’s Graduate Institute, and cosponsored by the Swiss Institute of Intellectual Property and […] Continue reading -> French Parliament To Require Disclosure Of Public Funds Used In R&D For New Drugs Entering Market 27/11/2019 Grace Ren The lower house of the French parliament has approved a milestone requirement that pharmaceutical companies must disclose the amount of public funding that was used in the research and development of new medicines entering the national market, as well as allowing those contributions to be factored into negotiations over final drug pricing. After being initially […] Continue reading -> Posts navigation Older postsNewer posts
Emergencies, Cervical Cancer, IP & Innovation Among Highlights Of Member State Consultations Ahead Of WHO Executive Board 09/01/2020 Editorial team Ahead of the upcoming WHO Executive Board meeting 3-8 February, WHO has launched a series of informal consultations this week with member state representatives on key issues that will be coming before the governing body – and ultimately the May meeting of the World Health Assembly (WHA). The detailed consultation agenda, published on the WHO […] Continue reading -> Creative Approaches To Improving Medicines Access – Lessons From The Hepatitis C Experience 06/12/2019 Elaine Ruth Fletcher The issues around access to medicines at affordable prices has galvanized civil society, the pharmaceutical industry, the research community, and politicians this year in oft-contentious debate that shows no sign of abating. A day-long session hosted by the Global Health Centre of Geneva’s Graduate Institute, and cosponsored by the Swiss Institute of Intellectual Property and […] Continue reading -> French Parliament To Require Disclosure Of Public Funds Used In R&D For New Drugs Entering Market 27/11/2019 Grace Ren The lower house of the French parliament has approved a milestone requirement that pharmaceutical companies must disclose the amount of public funding that was used in the research and development of new medicines entering the national market, as well as allowing those contributions to be factored into negotiations over final drug pricing. After being initially […] Continue reading -> Posts navigation Older postsNewer posts
Creative Approaches To Improving Medicines Access – Lessons From The Hepatitis C Experience 06/12/2019 Elaine Ruth Fletcher The issues around access to medicines at affordable prices has galvanized civil society, the pharmaceutical industry, the research community, and politicians this year in oft-contentious debate that shows no sign of abating. A day-long session hosted by the Global Health Centre of Geneva’s Graduate Institute, and cosponsored by the Swiss Institute of Intellectual Property and […] Continue reading -> French Parliament To Require Disclosure Of Public Funds Used In R&D For New Drugs Entering Market 27/11/2019 Grace Ren The lower house of the French parliament has approved a milestone requirement that pharmaceutical companies must disclose the amount of public funding that was used in the research and development of new medicines entering the national market, as well as allowing those contributions to be factored into negotiations over final drug pricing. After being initially […] Continue reading -> Posts navigation Older postsNewer posts
French Parliament To Require Disclosure Of Public Funds Used In R&D For New Drugs Entering Market 27/11/2019 Grace Ren The lower house of the French parliament has approved a milestone requirement that pharmaceutical companies must disclose the amount of public funding that was used in the research and development of new medicines entering the national market, as well as allowing those contributions to be factored into negotiations over final drug pricing. After being initially […] Continue reading -> Posts navigation Older postsNewer posts